Compare EDUC & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | BLRX |
|---|---|---|
| Founded | 1965 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.6M |
| IPO Year | 1995 | 2010 |
| Metric | EDUC | BLRX |
|---|---|---|
| Price | $1.58 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 37.5K | 14.7K |
| Earning Date | 05-19-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.86 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $22,913,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $2.15 |
| 52 Week High | $1.84 | $5.05 |
| Indicator | EDUC | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 54.03 |
| Support Level | $1.27 | $3.05 |
| Resistance Level | $1.67 | $3.51 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 63.33 | 49.57 |
Educational Development Corp distributes books and educational products and publications through its PaperPie and EDC Publishing divisions to individual consumers, book, toy and gift stores, libraries and home educators located throughout the United States. The company is the owner and exclusive publisher of Kane Miller children's books; Learning Wrap-Ups, maker of educational manipulatives; and SmartLab Toys, maker of STEAM-based toys and games. It also the exclusive United States Multi-Level Marketing (MLM) distributor of Usborne Publishing Limited (Usborne) children's books. It sell children's books, educational toys and games and other related products. It has two reportable segments: PaperPie and Publishing of which majority of revenue comes from Paperpie.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.